Amicus Therapeutics to Host Analyst Day 2018 Today in New York City
October 11 2018 - 7:00AM
Management and External Thought Leaders to
HighlightRobust Portfolio of Novel Therapies for Rare Metabolic
Diseases
Amicus Therapeutics, Inc. (NASDAQ: FOLD), a global biotechnology
company focused on discovering, developing and delivering novel
medicines for rare metabolic diseases will host its Analyst Day
today, October 11, 2018, in New York City from 8:30 a.m. until
12:30 p.m. Eastern Time.
John F. Crowley, Chairman and Chief Executive Officer of Amicus
Therapeutics, Inc., stated, “We are most pleased today to host our
Analyst Day to highlight the depth and breadth of our leading
portfolio of medicines for rare metabolic diseases. With one
globally approved medicine for Fabry disease, a differentiated
biologic for Pompe disease in the clinic and the recent addition of
fourteen new gene therapy programs into our pipeline, including two
clinical stage gene therapies for Batten disease, we are in a
stronger position than ever to become a leading global
biotechnology focused on transforming the lives of people living
with these rare, life-threatening conditions.”
Amicus Analyst Day Featured Discussion
Topics:
- Vision, Mission and Strategy
• John F. Crowley - Chairman and CEO, Amicus
Therapeutics
- Proof-of-Concept Data for AAV Gene Therapy Programs for
Neurologic Lysosomal Storage Disorders
• Kathrin Meyer, Ph.D. – Principal Investigator, Nationwide
Children’s Hospital Center for Gene Therapy •
Jay Barth, M.D. – Chief Medical Officer, Amicus
Therapeutics
- New Platforms for Gene Therapy in Rare Metabolic
Disorders • Jeff Castelli, Ph.D. –
Chief Portfolio Officer, Amicus Therapeutics •
James M. Wilson, M.D., Ph.D. – Professor of Medicine and
Pediatrics, Perelman School of Medicine • Hung
Do, Ph.D. – Chief Science Officer, Amicus Therapeutics
- AT-GAA Positive 18-Month Data from Phase 1/2 Study
(ATB200-02) for Pompe Disease • Mark
Roberts, M.D. - Dept. of Neurology, Salford Royal NHS Foundation
Trust
- Patient Advocacy and Personal Perspectives on Pompe
Disease: • Jayne Gershkowitz - Chief
Patient Advocate, Amicus Therapeutics • George
Fox - Dad and caregiver to son, Phoenix • Mike
Stanzione – courageously living with late onset Pompe
- Galafold Global Launch Updates •
Bradley Campbell – President and COO, Amicus Therapeutics
• Detlef Wolff – SVP, Head of International, Amicus
Therapeutics
The live event will be audio webcasted simultaneously and
accessible through the Events & Presentations page of the
Amicus Therapeutics website at http://ir.amicusrx.com/. The event
will be archived on the Company's website for approximately 90
days.
About Amicus TherapeuticsAmicus Therapeutics
(Nasdaq: FOLD) is a global, patient-centric biotechnology company
focused on discovering, developing and delivering novel
high-quality medicines for people living with rare metabolic
diseases. With extraordinary patient focus, Amicus
Therapeutics is committed to advancing and expanding a robust
pipeline of cutting-edge, first- or best-in-class medicines for
rare metabolic diseases. For more information please visit the
company’s website at www.amicusrx.com.
Forward Looking StatementThis press release
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995 relating to the
collaboration with the University of Pennsylvania, the recent
acquisition of Celenex, preclinical and clinical data, regulatory
strategy and the development of potential gene therapy product
candidates. The inclusion of forward-looking statements should not
be regarded as a representation by us that any of our plans will be
achieved. Any or all of the forward-looking statements in this
press release may turn out to be wrong and can be affected by
inaccurate assumptions we might make or by known or unknown risks
and uncertainties. For example, the benefits of this collaboration
may never be realized, the potential that results of clinical or
preclinical studies indicate that the product candidates are unsafe
or ineffective; the potential that it may be difficult to enroll
patients in our clinical trials; the potential that regulatory
authorities, including the FDA, EMA, and PMDA, may not grant or may
delay approval for our product candidates; the potential that
preclinical and clinical studies could be delayed because we
identify serious side effects or other safety issues; the potential
that we may not be able to manufacture or supply sufficient
clinical or commercial products; the potential that we will need
additional funding to complete all of our studies and manufacturing
and the potential that certain individuals may not continue to
support the development of product candidates. . In addition, all
forward-looking statements are subject to other risks detailed in
our Annual Report on Form 10-K for the year ended December 31, 2017
as well as our Quarterly Report on Form 10-Q for the quarter ended
June 30, 2018 filed August 7, 2018 with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
All forward-looking statements are qualified in their entirety by
this cautionary statement, and we undertake no obligation to revise
or update this presentation to reflect events or circumstances
after the date hereof.
CONTACTS:
Investors/Media:Amicus TherapeuticsSara
Pellegrino, IRCVice President, Investor Relations & Corporate
Communicationsspellegrino@amicusrx.com (609) 662-5044
Media / Multimedia Assets:Pure
CommunicationsJennifer
Paganellijpaganelli@purecommunications.com(347) 658-8290
FOLD–G
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Apr 2023 to Apr 2024